STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [Form 4] Guardant Health, Inc. Insider Trading Activity

Guardant Health (GH) CCO exercises 63,605 options and sells shares near $170

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported option exercises and share sales on August 10, 2026. He exercised stock options covering 63,605 shares of common stock, including 35,412 shares at an exercise price of $110.49 per share from an award granted August 3, 2021, which is now fully vested, and 28,193 shares at an exercise price of $28.37 per share from an award granted December 13, 2023 that continues to vest over a three-year period. Freeman then sold 63,605 shares of common stock in open-market transactions at weighted average prices per share ranging from approximately $167.12 to $170.67, with the exact breakdown of shares sold at each price available upon request as noted in the footnotes.

Positive

  • None.

Negative

  • None.
Insider Freeman Chris
Role Chief Commercial Officer
Sold 63,605 shs ($10.79M)
Approx. gross sale proceeds $10.79M
Approx. exercise cost $4.71M
Approx. pre-tax spread $6.07M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F5 35,412 $0.00 $0.00
Exercise Stock Option (Right to Buy) F6 28,193 $0.00 $0.00
Exercise Common Stock 35,412 $110.49 $3.91M
Exercise Common Stock 28,193 $28.37 $800K
Sale Common Stock F1 3,463 $167.3805 $580K
Sale Common Stock F2 7,365 $168.7909 $1.24M
Sale Common Stock F3 35,364 $169.6337 $6.00M
Sale Common Stock F4 17,413 $170.2407 $2.96M
Holdings After Transaction: Stock Option (Right to Buy) — 5,288 shares (Direct); Common Stock — 65,374 shares (Direct)
Footnotes (6)
  1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5. This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested.
  6. F6. This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
Options exercised 63,605 shares of Common Stock Total underlying shares from two Stock Option exercises on August 10, 2026
Exercise price (2021 award) $110.49 per share Stock Option (Right to Buy) for 35,412 shares, granted August 3, 2021, now 100% vested
Exercise price (2023 award) $28.37 per share Stock Option (Right to Buy) for 28,193 shares, granted December 13, 2023
Shares sold 63,605 shares of Common Stock Aggregate sellShares reported in transactionSummary for August 10, 2026
Sale price range (F1-F4) $167.12 to $170.67 per share Weighted average sale prices per share across multiple transactions, as described in footnotes F1–F4
Option expiration (2021 grant) August 2, 2031 Expiration date for Stock Option with $110.49 exercise price
Net buy/sell shares -63,605 shares transactionSummary netBuySellShares reported as net-sell direction
Stock Option (Right to Buy) financial
"The security title is listed as Stock Option (Right to Buy) for the derivative transactions."
weighted average sales price per share financial
"Footnotes F1–F4 state, Represents the weighted average sales price per share."
vested financial
"Footnote F5 notes the August 3, 2021 stock option award is now 100% vested."
equal monthly installments financial
"Footnote F6 describes remaining shares vesting in equal monthly installments over two years."

FAQ

What did Guardant Health (GH) executive Chris Freeman report in this Form 4?
Chris Freeman reported exercising stock options for 63,605 shares of Guardant Health common stock and selling 63,605 shares in open-market transactions on August 10, 2026, according to the Form 4 insider trading report.

How many Guardant Health (GH) shares did Chris Freeman sell and at what prices?
Chris Freeman sold a total of 63,605 shares of Guardant Health common stock at weighted average prices per share ranging from about $167.12 to $170.67, with full price-by-share details available upon request as disclosed.

What stock options did Chris Freeman exercise in this Guardant Health (GH) Form 4?
He exercised options covering 35,412 shares at $110.49 per share from an August 3, 2021 grant and 28,193 shares at $28.37 per share from a December 13, 2023 grant, receiving an equal number of Guardant Health common shares.

What is the vesting status of Chris Freeman’s Guardant Health (GH) option awards?
The August 3, 2021 option award for 35,412 shares is 100% vested. The December 13, 2023 award vests over three years: 33% vested on October 1, 2024, and the remaining 67% vests in equal monthly installments over the next two years.

Were Chris Freeman’s Guardant Health (GH) trades under a Rule 10b5-1 plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked as affirmatively used for these transactions, and the footnotes do not describe a trading plan, so no plan status is specified in the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Freeman Chris
(Last)(First)(Middle)
3100 HANOVER STREET
(Street)
PALO ALTO CALIFORNIA 94304
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026M35,412A$110.49100,786D
Common Stock08/10/2026M28,193A$28.37128,979D
Common Stock08/10/2026S3,463D$167.3805(1)125,516D
Common Stock08/10/2026S7,365D$168.7909(2)118,151D
Common Stock08/10/2026S35,364D$169.6337(3)82,787D
Common Stock08/10/2026S17,413D$170.2407(4)65,374D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$110.4908/10/2026M35,412 (5)08/02/2031Common Stock35,412$03,620D
Stock Option (Right to Buy)$28.3708/10/2026M28,193 (6)12/13/2033Common Stock28,193$01,668D
Explanation of Responses:
1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
5. This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested.
6. This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Chris Freeman08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR